I am Chief Drug Development Scientist at Cancer Research UK’s Centre for Drug Development where I have overseen the delivery of over 25 drug candidates into first-in-human clinical trials including cell therapies, vaccines, antibodies and small molecules. I have a PhD in pharmacology and previously held scientific leadership positions in metabolic and inflammatory diseases with Glaxo and Rhone-Poulenc Rorer. I have also worked in biotech and at Prolifix, led on the pre-clinical characterisation and early development of Belinostat, now an approved medicine for the treatment of peripheral T-cell lymphoma. I acts as a scientific advisor for a number of non-commercial and commercial research organisations and lecture in drug development on several MSc courses. I am a trustee and director of the PTEN research foundation and co-founded Duke Street Bio, an Immuno-oncology-focused drug discovery company.